Cargando…

Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease

Patients with chronic kidney disease (CKD) develop anemia largely because of inappropriately low erythropoietin (EPO) production and insufficient iron available to erythroid precursors. In four phase 3, randomized, open‐label, clinical trials in dialysis‐dependent and non–dialysis‐dependent patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koury, Mark J., Agarwal, Rajiv, Chertow, Glenn M., Eckardt, Kai‐Uwe, Fishbane, Steven, Ganz, Tomas, Haase, Volker H., Hanudel, Mark R., Parfrey, Patrick S., Pergola, Pablo E., Roy‐Chaudhury, Prabir, Tumlin, James A., Anders, Robert, Farag, Youssef M. K., Luo, Wenli, Minga, Todd, Solinsky, Christine, Vargo, Dennis L., Winkelmayer, Wolfgang C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543410/ https://www.ncbi.nlm.nih.gov/pubmed/35751858 http://dx.doi.org/10.1002/ajh.26644

Ejemplares similares

Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis
por: Sarnak, Mark J, et al.
Publicado: (2023)

Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO(2)VATE trials
por: Eckardt, Kai-Uwe, et al.
Publicado: (2020)

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO(2)TECT Randomized Clinical Trial of ESA-Treated Patients
por: Parfrey, Patrick S., et al.
Publicado: (2023)

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO(2)TECT Randomized Clinical Trial of ESA-Naïve Patients
por: Winkelmayer, Wolfgang C., et al.
Publicado: (2023)

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report
por: Sakurama, Keiki, et al.
Publicado: (2023)

Erythropoietic protoporphyria
por: Lecha, Mario, et al.
Publicado: (2009)

Correction to: Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report
por: Sakurama, Keiki, et al.
Publicado: (2023)

Implantable Loop Recorder Monitoring and the Incidence of Previously Unrecognized Atrial Fibrillation in Patients on Hemodialysis
por: Koplan, Bruce A., et al.
Publicado: (2021)

Microcytosis in Erythropoietic Protoporphyria
por: Graziadei, Giovanna, et al.
Publicado: (2022)

Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents
por: Kowalski, Heather, et al.
Publicado: (2023)

THE ERYTHROPOIETIC ACTION OF GERMANIUM DIOXIDE
por: Hammett, Frederick S., et al.
Publicado: (1922)

Erythrodontia in congenital erythropoietic porphyria
por: Bhavasar, Rashmi, et al.
Publicado: (2011)

Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease
por: Chertow, Glenn M., et al.
Publicado: (2017)

Vadadustat, a HIF Prolyl Hydroxylase Inhibitor, Improves Immunomodulatory Properties of Human Mesenchymal Stromal Cells
por: Zielniok, Katarzyna, et al.
Publicado: (2020)

Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
por: Xiong, Limei, et al.
Publicado: (2022)

Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria
por: Dickey, Amy K., et al.
Publicado: (2020)

Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults
por: Paulson, Susan K., et al.
Publicado: (2022)

DNA SYNTHESIS AND MITOSIS IN ERYTHROPOIETIC CELLS
por: Grasso, Joseph A., et al.
Publicado: (1967)

Congenital Erythropoietic Porphyria with Undescended Testis
por: Arora, Sandeep, et al.
Publicado: (2016)

Erythropoietic Factor in Human Mixed Saliva
por: Sitaramamurti, A.
Publicado: (1941)

The role of ClpX in erythropoietic protoporphyria
por: Whitman, Jared C., et al.
Publicado: (2018)

Erythropoietin and Non-Erythropoietic Derivatives in Cognition
por: Newton, Samuel S., et al.
Publicado: (2021)

An Atypical Case of Congenital Erythropoietic Porphyria
por: Sudrié-Arnaud, Bénédicte, et al.
Publicado: (2021)

Hypertrichosis and erythrodontia in congenital erythropoietic porphyria
por: Enciso, Leonardo
Publicado: (2021)

Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents
por: Karlsson, Torbjörn
Publicado: (2011)

Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2020)

ERYTHROPOIETIC CELL CULTURES FROM CHICK EMBRYOS
por: Hagopian, Helen K., et al.
Publicado: (1972)

CULTURE OF ERYTHROPOIETIC CELLS FROM CHICK BLASTODERMS
por: Chan, Lee-Nien L., et al.
Publicado: (1973)

UK experience of liver transplantation for erythropoietic protoporphyria
por: Dowman, Joanna K., et al.
Publicado: (2011)

CONGENITAL ERYTHROPOIETIC PORPHYRIA: TWO CASE REPORTS
por: Koley, Sankha, et al.
Publicado: (2011)

Laparoscopic Cholecystectomy in a Patient with Erythropoietic Protoporphyria
por: Roe, Thomas, et al.
Publicado: (2010)

Advances in the management of erythropoietic protoporphyria – role of afamelanotide
por: Lane, Ashley M, et al.
Publicado: (2016)

Scleritis in congenital erythropoietic porphyria – infective or inflammatory?
por: Sahay, Pranita, et al.
Publicado: (2018)

Ocular manifestations in patient with congenital erythropoietic porphyria
por: Isanta-Otal, C, et al.
Publicado: (2019)

Hemoglobin response to ferric citrate in patients with nondialysis‐dependent chronic kidney disease and iron deficiency anemia
por: Pergola, Pablo E., et al.
Publicado: (2018)

The Authors Reply
por: Sharma, Shilpa, et al.
Publicado: (2020)

Elevated Fibroblast Growth Factor 23 Levels Are Associated With Greater Diastolic Dysfunction in ESRD
por: Sharma, Shilpa, et al.
Publicado: (2019)

Elimination of Young Erythrocytes from Blood Circulation and Altered Erythropoietic Patterns during Paraquat Induced Anemic Phase in Mice
por: Bhardwaj, Nitin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3ii6gsmejbe6mgn73sevlo4ore